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Cancer-induced cachexia is an uncomfortable paraneoplastic
syndrome which worsens the quality of life of patients with
advanced malignancies. A number of studies have been conducted
to explore the factors responsible for this cachexia, and it has been
revealed that elevated blood levels of tumour necrosis factor a
(TNF-a), interleukin 1 (II-1), IL-6, IL-11, g-interferon, leukaemia
inhibitory factor or 24 kDa proteoglycan may induce cachexia
(Beutler et al, 1986; Moldawer et al, 1988; Metcalf et al, 1990;
Matthys et al, 1991; Strassmann et al, 1992a; Ohsumi et al, 1994;
Todorov et al, 1996). One of these factors, IL-6, is a pleiotropic
cytokine physiologically involved in the differentiation of myeloid
and neuronal cells, and pathologically involved in the early host
response to infection and injury (Kishimoto, 1989), in the prolifer-
ation of myeloma (Kawano et al, 1988), urological cancer cells
(Miki et al, 1989; Okamoto et al, 1997a,b) and possibly breast
cancer cells (Chiu et al, 1996), and in the development of hyper-
calcaemia and osteolytic metastases (De La Mata et al, 1995). A
series of studies have suggested that IL-6 secreted from tumour
cells is one of the cachectic factors in animal models of murine
colon cancer or of xenograft tumours in athymic nude mice
(Greenberg et al, 1992; Strassmann et al, 1992b; Ohe et al, 1993;
Fujimoto-Ouchi et al, 1995; Yasumoto et al, 1995; Billingsley et
al, 1996; Kajimura et al, 1996; Mori et al, 1996; Ohira et al, 1996;
Tsujinaka et al, 1996). Recently, clinical reports have also
suggested that elevated IL-6 levels in the sera of patients with
oesophageal cancer correlate with their bodyweight loss (Oka et
al, 1996), and that a decrease in serum IL-6 levels induced by
medroxyprogesterone acetate (MPA) correlates with a reversion
of bodyweight loss in patients with advanced breast cancer
(Yamashita et al, 1996). The former report noted that IL-6 is over-
expressed in tumour cells and suggested that IL-6 secreted from
the tumour cells may be one of the causes of cancer-induced
cachexia. However, the latter report did not explore the mecha-
nisms responsible for the reduction in the serum IL-6 levels of
patients induced by MPA.
MPA has been used as an endocrine therapeutic agent for the
treatment of hormone-responsive breast cancer. One of the adverse
effects of MPA is bodyweight gain of the patients (Van Veelen et
al, 1986). It has been reported, however, that concomitant adminis-
tration of MPA reduces the nausea and anorexia induced by the
administration of cytotoxic agents, and subsequently reverses
bodyweight loss (Tominaga et al, 1994). Based on these findings, a
clinical trial using MPA as an anticachectic agent has been under-
taken in patients with various malignancies which are not hormone
responsive (Downer et al, 1993).
To elucidate the mechanisms of action of the anticachectic
effect of MPA, its effects on IL-6 secretion from the KPL-4 human
breast cancer cell line were explored both in vitro and in vivo in
this study. This KPL-4 cell line was recently established in our
laboratory and is the first human breast cancer cell line to secrete
IL-6 into medium and to induce cachexia when injected into
female athymic nude mice (Kurebayashi et al, 1997). The experi-
mental results in this study suggest that an inhibitory effect of
MPA on IL-6 secretion from tumour cells may, at least in part,
cause the anticachectic effect of MPA.
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Cell line and cell culture
The KPL-4 cell line was recently established and its characterization
has been published elsewhere (Kurebayashi et al, 1997). In brief,
this cell line was derived from the malignant pleural effusion of a
Japanese patient with recurrent breast cancer. The recurrent disease
exhibited an inflammatory skin metastasis. All the Erb B family
receptors are expressed in this cell line. Neither oestrogen nor pro-
gesterone receptors are expressed. Injections of this cell line into the
mammary fat pad of female nude mice produce rapid-growing
tumours and induce severe cachexia. Immunoreactive IL-6 is
detected in both culture medium and the serum of recipient mice.
KPL-4 cells are routinely cultured in Dulbecco￿s modified Eagle
medium (DMEM) supplemented with 5% fetal bovine serum (FBS).
The population-doubling time is approximately 48 h in the routine
medium. For IL-6 measurement of the culture medium, 1 ´ 105
KPL-4 cells per well were inoculated into 12-well plates (SB
Medical, Tokyo, Japan) with the routine medium. The medium was
changed to DMEM supplemented with 5% FBS (ICN
Biochemicals, Costa Mesa, CA, USA) plus 10—1000 nM MPA
(kindly provided by Kyowa Hakko, Tokyo, Japan) or 0.1—10 ng ml—1
TNF-a (Gibco, Gaithersburg, MD, USA), or both, 4 days after the
inoculations. The culture medium and cells were collected after a
48-h incubation. The IL-6 concentration in the medium was
measured as described below. After cell dispersion with 0.05%
trypsin plus 0.02% EDTA in phosphate-buffered saline (PBS) for
over 10 min, the cell number per well was measured with a Coulter
counter (Coulter Electronics, Harpenden, UK). For RNA extraction,
semiconfluent KPL-4 cells in T-25 flasks (Corning, Tokyo, Japan)
were incubated with DMEM supplemented with 5% FBS plus
100—1000 nM MPA, 10 ng ml—1 TNF-a or both for 48 h, and then the
treated cells were collected with a trypsin/EDTA solution. After
washing with PBS, the cell pellet was stored at —80°C before use.
IL-6 measurement
IL-6 concentrations in cultured medium and mouse serum were
measured with a chemiluminescent enzyme immunoassay kit
(Fujirebio, Tokyo, Japan) according to the manufacturer￿s recom-
mendations. Briefly, a mouse anti-human IL-6 monoclonal antibody
(HH 61-10) was used as the first antibody, and a mouse anti-human
IL-6 monoclonal antibody labelled with alkaline phosphatase
(HH 61-2 Fab¢) was used as the second one. After removing the
unbound second antibody, 3-(2¢-spiroadamantane)-4-methoxy-4-
(3¢¢-phosphoryloxy)phenyl-1,2-dioxetane disodium salt was added.
Chemiluminescence was measured with a Lumipulse luminometer
(Fujirebio). As the standard, 20—1000 pg ml—1 of human recombi-
nant IL-6 was used. In this assay, no cross-reactivity against recom-
binant mouse IL-6 was observed. The minimal detectable
concentration of IL-6 was 0.2 pg ml—1. The intra-assay coefficients
of variation for the high, middle and low sample levels were 2.8%,
2.2% and 3.8% respectively. The interassay coefficients of variation
for these sample levels were 3.6%, 4.9% and 8.6% (Takemura et al,
1996). Because the IL-6 concentration in the fresh medium was
undetectable and increased linearly for at least 2 days, IL-6 secretion
into the medium was defined as follows:
IL-6 secretion Concentration of IL-6 ´ volume of medium
per cell per 48 h
=
Mean cell number
Semiquantitative reverse transcription polymerase
chain reaction (RT-PCR) for IL-6 mRNA
Total cellular RNA from KPL-4 cells was extracted with a TRIzol
RNA extraction kit (Gibco) according to the manufacturer￿s recom-
mendations. One microgram of total RNA and oligo (dT)18 primer
(final concentration 1 mM) in 12.5 ml of diethyl pyrocarbonate-treated
water was heated to 70°C for 2 min followed by cooling on ice for
1 min. cDNA synthesis was initiated with 200 units of recombinant
Molony-murine leukaemia virus reverse transcriptase (Clontech
Laboratories, Palo Alto, CA, USA) under conditions recommended
by the manufacturer, and the reaction was allowed to proceed at 42°C
for 1 h. The reaction was terminated by heating at 94°C for 5 min.
cDNA was finally dissolved to a final volume of 100 ml by adding
80 ml of diethyl pyrocarbonate-treated water and was frozen at —20°C
before use. Oligonucleotide primers for RT-PCR were designed
using published sequences of human IL-6 and b-actin, and were
synthesized by the solid-phase triester method. The primers used in
this study were: IL-6, 5¢-GAACTCCTTCTCCACAAGCG-3¢
(sense) and 5¢-GAATCCAGATTGGAAGCATCC-3¢ (antisense);
and  b-actin, 5¢-TGACGGGGTCACCCACACTGTGCCCATCTA-
3¢ (sense) and 5¢-CTAGAAGCATTTGCGGTGGACGATG-
GAGGG-3¢ (antisense). The expected sizes from reported cDNA
sequences were 316 bp and 610 bp for the IL-6 and b-actin genes
respectively. Each RT-PCR reaction contained 1:100 of cDNA
(equivalent to a cDNA amount from 10 ng of initial total RNA),
200 nM concentrations of each primer, 200 mM deoxynucleotide
triphosphates, 10 mM tris-HCl (pH 8.8), 1.5 mM, magnesium chlo-
ride, 50 mM potassium chloride, 0.08% Nonident P40, and one unit
of recombinant Thermus aquatics DNA polymerase (MBI
Fermentas, Vilnius, Lithuania) in a final volume of 20 ml. After an
initial denaturation at 94°C for 4 min, 25 cycles of denaturation for b-
actin and 35 cycles for IL-6 (94°C for 15 s), annealing (60°C for b-
actin and 58°C for IL-6 for 15 s), and extension (72°C for 30 s) were
performed on a DNA Thermal Cycler 2400 (PC-960G Microplate
Gradient Thermal Cycler, Mortlake, Australia). The final extension
was performed for 5 min. The number of cycles in the RT-PCR was
determined to obtain logarithmic amplification of both genes for
semiquantitative analysis of the expression levels of the genes. After
visualization of the RT-PCR products by 1.2% agarose gel stained
with ethidium bromide, gel images were obtained using the FAS-II
UV-image analyzer (Toyobo, Tokyo, Japan), and the densities of the
products were quantified using the Quantity One version 2.5 (PDI,
Huntington Station, NY, USA). The relative expression levels were
calculated as the density of the product of the IL-6 gene divided by
that of the b-actin gene from the same cDNA.
Animal experiments
Semiconfluent KPL-4 cells were trypsinized and harvested, and
viable cells were counted in a haemocytometer using trypan blue
exclusion. To investigate the effects of MPA on KPL-4 tumour
growth, IL-6 secretion and mouse cachexia, approximately 2 ´ 106
KPL-4 cells were injected into the right and left mammary fat pads
of 4-week-old female nude mice (Clea, Tokyo, Japan). In the
MPA-treated group, 100 mg kg—1 MPA was intramuscularly
administered twice every week for between 3 and 7 weeks after the
cell injections. The same volumes of vehicle (sesame oil) were
administered in the control group in the same manner. Five mice
(ten tumours) were treated in each group. Three-dimensional
tumour size was measured with calipers every week after the cell
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before the administration. Tumour volume was calculated as the
product of the largest diameter, the orthogonal measurement and
the tumour depth. Mean tumour volume was calculated as the sum
of tumour volumes divided by the number of tumours. All mice
were sacrificed by cervical dislocation 7 weeks after the cell injec-
tions. After measurement of tumour weight, tumour samples were
fixed with 5% buffered formalin and embedded in paraffin for
morphological analysis. Then, mouse blood was collected, and the
serum was stored at —80°C before use.
To clarify the induction of mouse cachexia by transplantation
with KPL-4 cells, the bodyweight of intact female mice was
measured every week and the recovery of bodyweight loss after
tumour removal was observed in separate experiments.
The animal protocols for these experiments were approved by
the Animal Care and Use Committee of Kawasaki Medical
School.
Statistical analysis
The IL-6 secretion, tumour volume, tumour weight, mouse body
weight and serum IL-6 concentration of mice were expressed as
means ± s.e. These values for the control and treated groups were
compared using ANOVA with StatView computer software
(ATMS, Tokyo, Japan). All the experiments in this study were
repeated at least twice and the reproducibility of the results was
confirmed.
RESULTS
MPA reduces both IL-6 secretion and IL-6 mRNA level
in KPL-4 cells
As shown in Figure 1A, a 48-h incubation with 10—1000 nM MPA
dose-dependently decreased basal IL-6 secretion into medium
from KPL-4 cells to 0.57-fold for 10 nM, 0.45-fold for 100 nM, and
0.37-fold for 1000 nM. In contrast, TNF-a dose-dependently stim-
ulated IL-6 secretion to 1.17-fold for 0.1 ng ml—1, 2.17-fold for
1.0 ng ml—1, and 8.07-fold for 10 ng ml—1 (Figure 1B). TNF-a-stim-
ulated IL-6 secretion was dose-dependently inhibited by MPA to
0.61-fold for 100 nM MPA and 0.42-fold for 1000 nM MPA (Figure
1C). In addition, changes in IL-6 mRNA levels were investigated
by a semiquantitative RT-PCR method. As shown in Figure 2A,
48 h incubation with 100 or 1000 nM MPA dose-dependently
lowered the basal IL-6 mRNA expression level in KPL-4 cells.
The relative IL-6 expression ratios compared with b-actin expres-
sion (internal control) were 0.95 for the control, 0.20 for 100 nM
MPA and 0 for 1000 nM MPA. The IL-6 mRNA level induced by
TNF-a was also inhibited by MPA (Figure 2B).
MPA decreases serum IL-6 levels and preserves
bodyweight of female nude mice bearing KPL-4
tumours
Intramuscular injections of 100 mg kg—1 MPA twice a week for 4
weeks did not significantly affect KPL-4 tumour growth, but did
significantly preserve mouse body weight (Figure 3A and B).
Tumour weights and bodyweights 7 weeks after the cell injections
in each group were 0.43 ± 0.11 g and 19.2 ± 0.7 g for the control
group and 0.47 ± 0.08 g and 23.2 ± 0.7 g for the MPA-treated group
respectively (P = 0.013 comparing the two groups for bodyweight).
The bodyweight in the control group was significantly lower
than that of the intact mice and that of the MPA-treated group
(Figure 3B). No difference in bodyweight was observed between
the intact mice and MPA-treated mice. In addition, the mice
bearing KPL-4 transplanted tumours completely recovered body-
weight loss after tumour removal (data not shown). These findings
suggest that the mouse bodyweight loss was induced by the KPL-4
transplanted tumours, and that MPA-treatment resulted in
Inhibition of IL-6 secretion by MPA 633
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Figure 1 Effect of MPA (A), TNF-a (B) and their combination (C) on IL-6
secretion into medium from KPL-4 human breast cancer cells. Semiconfluent
cells were incubated with the routine medium with 10–1000 nM MPA, 0.1–
10 ng ml–1 TNF-a, or 10 ng ml–1 TNF-a plus 100–1000 nM MPA for 48 h. IL-6
concentrations in the medium and cell number per well were measured, and
IL-6 secretion per cells per 48 h was calculated as described in Materials and
methods. The values represent means ± s.e. of triplicate samples. **P < 0.01
compared with respective controls (A, B) or the TNF-a-stimulated value (C)complete recovery of bodyweight loss in the mice bearing KPL-4
tumours.
The serum IL-6 levels of the recipient mice were also measured
7 weeks after the cell injections. The values were 57.6 ± 20.3 pg
ml—1 for the control group and 8.9 ± 2.5 pg ml—1 for the MPA-
treated group. MPA significantly reduced serum IL-6 levels in
nude mice bearing KPL-4 tumours (P = 0.019). IL-1b, IL-11,
TNF-a, leukaemia inhibitory factor and g-interferon were not
detectable in the serum of the mice bearing KPL-4 tumours in a
preliminary experiment. In addition, the IL-6 concentration in the
MPA-treated tumours was significantly lower than that in the
control tumours (data not shown). Histological examination
revealed no remarkable change in tumour cell morphology or
mononuclear cell infiltration in the MPA-treated tumours.
DISCUSSION
MPA is a synthetic analogue of progesterone, which has been
widely used in clinics as a second-line endocrine therapeutic agent
for the treatment of patients with recurrent breast cancer. Although
the efficacy of MPA has been reported to be comparable or supe-
rior to that of tamoxifen, a non-steroidal anti-oestrogen, tamoxifen
has been recognized as a first-line endocrine therapeutic agent
because of fewer adverse effects (Van Veelen et al, 1986). One of
the main adverse effects of MPA is weight gain of patients.
However, the results of a recent clinical trial suggest that this
adverse effect results in improvement of the anorexia and body-
weight loss induced in patients by cytotoxic agents (Tominaga et
al, 1994). Moreover, MPA has been used as an anticachectic agent
for patients with non-breast malignancies in a clinical trial
(Downer et al, 1993). A similar clinical trial has been conducted
using another synthetic progestin, megestrol acetate (Gebbia et al,
1996). To explore the action mechanisms of MPA responsible for
the anticachectic effect, some clinical and experimental studies
have been conducted. A very recent report suggested that MPA
reduces the production of cytokines including IL-6 by peripheral
blood mononuclear cells of cancer patients (Montovani et al,
1997). Another report suggested that MPA reduces the serum IL-6
levels of patients with advanced breast cancer and preserves the
bodyweight of these patients (Yamashita et al, 1996). Although a
series of experimental studies and some clinical studies suggest
that IL-6 secreted from tumour cells may mediate cancer-induced
cachexia, the effects of MPA on IL-6 production and secretion in
tumour cells still remain to be elucidated. These findings prompted
us to explore the direct action of MPA on IL-6 expression from
human breast cancer cells.
We recently established a new human breast cancer cell line,
KPL-4, from a patient with recurrent breast cancer (Kurebayashi et
al, 1997). During an animal experiment, we unexpectedly found
that KPL-4 transplanted tumours induced severe cachexia in the
recipient mice. Subsequent studies revealed that KPL-4 cells
secrete immunoreactive IL-6 into medium and that serum IL-6
levels correlate with the weights of KPL-4 tumours in recipient
mice (Kurebayashi et al, 1998). These findings suggest that IL-6
secretion from KPL-4 cells may be a main cause of cachexia in
this model system. Therefore, in this study, we decided to use this
634 J Kurebayashi et al
British Journal of Cancer (1999) 79(3/4), 631–636 © Cancer Research Campaign 1999
C
o
n
t
r
o
l
T
N
F
-
a
C
o
n
t
r
o
l
T
N
F
-
a
 
+
 
M
P
A
1
0
–
7
 
M
 
M
P
A
1
0
–
6
 
M
 
M
P
A
IL-6
IL-6
b-actin
b-actin
ab c
ab c
B
A
2000
1500
1000
500
0
1234567
Weeks after inoculation
T
u
m
o
u
r
 
v
o
l
u
m
e
 
(
m
m
3
)
A
B
B
o
d
y
 
w
e
i
g
h
t
 
(
g
)
25
20
15
1234567
Weeks after inoculation
Figure 2 Semiquantitative RT-PCR for the expression of IL-6 mRNA. One
microgram of total RNA extracted from untreated or treated KPL-4 cells was
reverse transcribed, and 1:100 of cDNA was amplified by PCR. Primers
specific for IL-6 and b-actin (internal control) cDNAs generated fragments of
316 bp and 610 bp respectively. (A) a, control; b, treated with 100 nM MPA;
c, treated with 1000 nM MPA. (B) a, control; b, treated with 10 ng ml–1 TNF-a;
c, treated with 10 ng ml–1 TNF-a plus 1000 nM MPA Figure 3 Effect of MPA on tumour growth (A) and bodyweight (B) in nude
mice bearing KPL-4 transplanted tumours. Approximately 2 ´ 106 cells were
injected into the mammary fat pad of 4-week-old athymic nude mice. MPA
(100 mg kg–1) was administered i.m. twice a week from 3 to 7 weeks after the
cell inoculations. Bodyweight of intact mice was also measured to clarify the
cachectic effect of KPL-4 transplanted tumours. The values represent mean
tumour volumes of ten tumours (A) or mean bodyweights of five mice (B) in
each group (l l, control; •, MPA-treated; s s, intact mice). Bars, s.e. *P < 0.05;
**P < 0.01 compared with respective controlsmodel system to explore possible mechanisms of action of MPA
responsible for cancer-induced cachexia.
In the present study, we demonstrate for the first time that MPA
significantly reduces both IL-6 secretion into medium and IL-6
mRNA levels in a human breast cancer cell line (Figure 1).
Moreover, MPA also suppresses TNF-a-stimulated IL-6 secretion
and IL-6 mRNA levels in this cell line (Figure 2). TNF-a is known
to be one of the most potent activators of IL-6 expression
(Kishimoto, 1989). Because we supposed that IL-6 secretion from
tumour cells should be regulated by some other cytokines through
paracrine pathways in vivo, we chose to investigate TNF-a in this
study. In addition, the serum IL-6 levels of mice bearing breast
tumours were lowered by MPA without affecting tumour growth
(Figure 3A). This result agrees with clinical data showing that a
reduction in serum IL-6 levels of patients with advanced breast
cancer do not correlate with the anti-tumour effect of MPA
(Yamashita et al, 1996). More interestingly, the reduction in the
serum IL-6 levels induced by MPA correlated with reversion of
bodyweight loss in the recipient mice (Figure 3B). These findings
suggest that a direct effect of MPA on IL-6 secretion from tumour
cells may be the main cause of the anticachectic effect of MPA. In
our preliminary experiment, IL-1b, IL-11, TNF-a, leukaemia
inhibitory factor and g-interferon were not detectable in the serum
of the mice bearing KPL-4 tumours. However, because some other
cachectic factors have been reported and the serum levels of these
factors were not systematically investigated in this study, it might
be possible that another factor is the main cause of cachexia in this
model system. Therefore, further analysis is needed to clarify the
role of IL-6 in cancer-induced cachexia.
IL-6 production and secretion are known to be stimulated by
lipopolysaccharide and cytokines, such as TNF-a and IL-1
(Okamoto et al, 1996a,b) in some tumour cells. The regulatory
mechanisms of IL-6 expression have been also studied in various
normal cells, such as fibroblasts, macrophages, endothelial cells,
epidermal cells, keratinocytes and synovial cells (Kishimoto,
1989). However, only in a recent report has it been suggested that
MPA reduces IL-6 secretion from the peripheral blood mono-
nuclear cells of cancer patients (Montovani et al, 1997). MPA is
known to bind not only to progesterone receptors but also to gluco-
corticoid and androgen receptors (Poulin et al, 1989; Narita et al,
1995) Because KPL-4 cells used in this study do not express either
oestrogen or progesterone receptors, it is conceivable that MPA
may act as a glucocorticoid or androgen through glucocorticoid or
androgen receptors. Our preliminary results suggest that hydro-
cortisone also reduces both basal and TNF-a-stimulated IL-6
secretion from KPL-4 cells (unpublished data). Further analysis is
needed to elucidate the signalling pathway of MPA responsible for
the inhibition of IL-6 expression in this cell line.
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